The Indian Institute of Technology (IIT) Madras has launched a first-of-its-kind cancer genome database to facilitate advanced research on cancer in India. This initiative, under the Bharat Cancer Genome Atlas (BCGA), aims to bridge the existing gap in the genomic landscape of Indian cancer patients, particularly in breast cancer research.
Despite India’s high cancer incidence, the country has been underrepresented in global cancer genome studies. As a result, specific genetic variants of Indian cancers remain inadequately documented, limiting their inclusion in diagnostic kits and drug development.
The Bharat Cancer Genome Atlas (BCGA) serves as a compendium of genetic variants representing the contemporary Indian breast cancer population. It provides valuable insights into early diagnostics, disease progression, and treatment outcomes. IIT Madras collaborated with Karkinos Healthcare, Mumbai; the Chennai Breast Clinic; and Cancer Research and Relief Trust, Chennai to analyze the data and compile an anonymized summary of genetic variants from Indian breast cancer samples.
Led by IIT Madras’ Centre of Excellence on Cancer Genomics and Molecular Therapeutics, the research was funded under the Government of India’s ‘Institutions of Eminence’ initiative.
This database will be an invaluable resource for identifying cancer-specific biomarkers in India, which will facilitate early detection of breast cancers and support the discovery of novel drug targets for improved treatment strategies tailored to the Indian population, said S. Mahalingam, Head, Centre of Excellence on Cancer Genomics and Molecular Therapeutics, IIT Madras.
BCGA is designed to host data from researchers working on cancer genomics across different cancer types. The database will be open to accepting submissions and will play a key role in identifying biomarkers to monitor high-risk groups, track cancer progression, design personalized treatment strategies, and evaluate treatment outcomes.
Additionally, the genome database will provide insights into the genetic basis of cancer progression and evolution. It aims to drive a shift in India’s biomedical research and healthcare system toward personalized medicine, where an individual’s genetic and molecular information is incorporated into clinical decision-making, thereby improving patient care standards.
